

2020



PROGRAM



VIRTUAL FOR 2020

A photograph of two hands shaking in a firm grip, overlaid with a semi-transparent purple box containing the text 'VIRTUAL FOR 2020'. The background is a soft-focus image of the handshake.

CANCER CARE
AT THE CROSSROADS

A photograph of a person in a white lab coat looking through a microscope, overlaid with a semi-transparent purple box containing the text 'CANCER CARE AT THE CROSSROADS'. The background is a soft-focus image of the person using the microscope.

 **A VIRTUAL EVENT FOR 2020**
September 24 & 25, 2020

A small calendar icon is positioned to the left of the text 'A VIRTUAL EVENT FOR 2020'. The text is in a bold, sans-serif font.

Two-day International Summit on Innovation, Clinical Benefit and Cost

Sponsors



2:30 to 2:35 pm

Log On and Virtual Housekeeping

2:35 to 3:00 pm

Welcome and Opening Remarks

Setting the Stage



PETER PISTERS, MD
President
The University of Texas
MD Anderson Cancer Center



MIKE MEYER
Founder and President
Meyer Consulting

3:00 to 4:15 pm

Round Table 1

Cancer Care Through the Lens of Health Plans, Academic Centers, Pharma and Provider Groups
- What Has Happened in the Last 12 Months



Opening Remarks/Moderator
MACE L. ROTHENBERG, MD
Chief Medical Officer, Pfizer
Pfizer Inc



Panelist
CLIFFORD HUDIS, MD
Chief Executive Officer
American Society of Clinical
Oncology (ASCO)



Panelist
MAUREEN E. SULLIVAN, MPP
Chief Strategy and Innovation Officer
Blue Cross Blue Shield Association



Panelist
WILLIAM L. HENRICH, MD, MACP
President and Professor of Medicine
UT Health San Antonio



Panelist
PETER PISTERS, MD
President
The University of Texas
MD Anderson Cancer Center

4:15 to 4:30 pm

Break

All times EDT

Program: Thursday, September 24

4:30 to 5:45 pm

Round Table 2

The Future of Cancer Science as Survivorship and New Modalities of Care Take Hold



Opening Remarks/Moderator

JAMES GULLEY, MD, PhD

Chief, Genitourinary Malignancies Branch;
Director, Medical Oncology Services, Center
for Cancer Research, National Cancer
Institute, National Institutes of Health



Panelist

STEPHEN ALBERT JOHNSTON

CEO, Calviri, Inc.
Director, Center for Innovations in
Medicine, Biodesign Institute
Arizona State University



Panelist

MICHAEL F. MURRAY, MD


Director of Clinical Operations
Center for Genomic Health
Yale School of Medicine



Panelist

ANDREW SCHMELTZ, MBA

Global President and General Manager
Pfizer Oncology
Pfizer Inc



Panelist

MICHEL SADELAIN, MD, PhD

Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center

Round table 2

All times EDT

Program: Friday, September 25

9:30 to 10:45 am

Round Table 3

Improving Patient Outcomes, Patient Experience and Provider Decision Making



Opening Remarks/Moderator

STEVEN PESKIN, MD, MBA, FACP

Executive Medical Director
Horizon Blue Cross Blue Shield of New Jersey



Panelist

CATHERINE M. ALFANO, PhD

Vice President, Cancer Care
Management and Research, Northwell
Health Cancer Institute; Former VP,
American Cancer Society (ACS)



Panelist

JOANNE M. CONROY, MD

CEO and President
Dartmouth-Hitchcock



Panelist

MARGARET B. ROW, MD, MBA, FACP

Clinical Chief of Oncology
Summit Medical Group Cancer Center



Panelist

KETAN PARANJAPE, MBA

Vice President of Diagnostic
Information Solutions
Roche Diagnostics

Round table 3

10:45 to 10:55 am

Break

10:55 am to 12:10 pm

Round Table 4

The Challenges Facing Health Plans, Providers and Governments in Financing Expensive Innovative Cancer Treatments



Opening Remarks/Moderator
JONATHAN D. ROCKOFF
Deputy Chief,
Health and Science Bureau
The Wall Street Journal



Panelist
GRACE GRAHAM, MPP
Health Policy Director
Senate HELP Committee;
Chairman, Senator Lamar Alexander



Panelist
GLEN STETTIN, MD
Senior Vice President and Chief
Innovation Officer
Express Scripts & Cigna Health Services



Panelist
RICHARD SULLIVAN, MD, PhD
Director, Institute for Cancer Policy;
Professor of Cancer and Global Health, King's
College London



Panelist
EILEEN O'DONNELL, MBA
Executive Director
Northwell Health Cancer Institute

Round table 4

12:10 to 12:20 pm

Break

12:20 to 1:35 pm

Round Table 5

A Look Forward: Perspectives on the Future of Health Care and Cancer Care as we approach the next decade



Opening Remarks/Moderator
JACQUE SOKOLOV, MD
Chairman and CEO
SSB Solutions



Panelist
BENJAMIN G. NEEL, MD, PhD
Professor of Medicine
Director, Laura and Isaac Perlmutter Cancer
Center Laura and Isaac Perlmutter Cancer Center
at NYU Langone Health



Panelist
ARTHUR KLEIN, MD
President
Mount Sinai Health Network



Panelist
ALEXANDER EGGERMONT, MD, PhD
Scientific Director, Princess Máxima Center for
Pediatric Oncology, the Netherlands; President,
European Academy Cancer Sciences;
Coordinator, German CCC Network and Creation
of Multi-site National Cancer Institute



Panelist
HAROLD PAZ, MD
EVP and Chancellor for Health Affairs,
The Ohio State University;
Chief Executive Officer
Ohio State Wexner Medical Center

Round table 5

Panelists



CATHERINE M. ALFANO, PhD

*Vice President, Cancer Care Management and Research,
Northwell Health Cancer Institute*

Catherine Alfano, PhD is an international leader in cancer survivorship and cancer rehabilitation. At Northwell Health, she leads the development and implementation of a high-quality cancer survivorship program to improve long-term patient outcomes while reducing unnecessary costs as a result of more timely and effective care. She also oversees new research development and training programs and research projects. Before joining Northwell, she served as the Vice President of Survivorship at the American Cancer Society and as Deputy Director of the National Cancer Institute's Office of Cancer Survivorship.

Dr. Alfano's research aims to speed the effective translation of research into practice and inform supporting policy to optimize patient outcomes and clinic efficiency, address provider shortages, and decrease healthcare costs. This research focuses on: 1) Domestic and global efforts to improve care delivery for oncology, cancer rehabilitation, and survivorship; 2) Integrating multi-source Big Data to generate insights for predictive and prescriptive analytics and creating mobile health and other digital health tools for better-personalized care; 3) Incorporating rehabilitation, healthy behavior change, and self-management into oncology and follow-up care; and 4) The integration of biological and behavioral pathways governing health, accelerated aging, function, and cancer prognosis.

In addition to her roles at Northwell, she has led work with the American Society of Clinical Oncology to help American healthcare systems develop risk & need-stratified survivorship care that focuses on helping patients self-manage their health and delivers care outside of clinic walls. She has held leadership positions at the Society of Behavioral Medicine, the American Society of Clinical Oncology, and the American Congress of Rehabilitation Medicine.



JOANNE M. CONROY, MD

*CEO, and President,
Dartmouth-Hitchcock*

Dr. Conroy was selected by the Board of Trustees in June 2017, as President and CEO of Dartmouth-Hitchcock and Dartmouth-Hitchcock Health.

As CEO of New Hampshire's only academic health system, Dr. Conroy has overseen significant positive changes, including a dramatic turnaround in the D-HH system's financial performance, the announcement of two major new expansion projects and a strategic planning process.

From FY2017 to FY2018, D-HH reversed a \$7 million operating deficit posting a positive margin of \$47 million in FY18. The health system is now in its third consecutive year of positive financial performance.

Dr. Conroy is a committed leader in advancing equity in the workplace. She is a co-founder of "Women of Impact," a nonpartisan group of 60 female health care leaders representing all sectors of the health care industry across the nation. She was also instrumental in D-HH becoming one of the founding signatories of the TIME'S UP Healthcare initiative, which aims to increase safety and gender equity in the health care industry.

She was named one of the "100 Most Influential People in Healthcare" by Modern Healthcare in 2018 and was included on their inaugural listing of Women Leaders Luminaries in 2019. Prior to joining Dartmouth, Dr. Conroy served as CEO of Lahey Hospital & Medical Center in Burlington, MA, and as Chief Health Care Officer for the Association of American Medical Colleges in Washington, DC.

She received her undergraduate degree in chemistry from Dartmouth College, and her MD from MUSC, where she completed her residency in anesthesiology, serving as Chief Resident for one year. Dr. Conroy is board certified with the American Board of Anesthesiologists, attained a Certificate of Added Qualifications in Pain Management, and is a diplomat with the American Academy of Pain Management.



ALEXANDER EGGERMONT, MD, PhD

Scientific Director, Princess Máxima Center for Pediatric Oncology, the Netherlands; President, European Academy Cancer Sciences; Coordinator, German CCC Network and Creation of Multi-site National Cancer Institute

Full Professor of Oncology (2012-20) (Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Past Director General Gustave Roussy Cancer Institute. Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models, drug development.

Scientific Output: is the author or co-author of > 800 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 100; > 50000 citations.

International functions:

- DKFZ-NCT/Deutsche Krebshilfe: Coordinator German National Center for Tumors Network, 2020 - ...
- European Academy of Cancer Sciences: President, 2010-2020
- Cancer Core Europe: President, 2014-2020
- ECCO: Past President
- EORTC: Past President
- ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board
- AACR: Past Deputy Editor of Clinical Cancer Research, 2001-2009
- Deutsche Krebshilfe: Chair International Jury for Comprehensive Cancer Centers Program, 2008-2020
- European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:

- Presidential Medical, Kazakhstan (2014) Legion d'Honneur, France (2015)



GRACE GRAHAM, MPP

Health Policy Director
Senate HELP Committee – Chairman, Senator Lamar Alexander

Grace Graham is Health Policy Director for Lamar Alexander (R-TN), Chairman of the Health, Education, Labor, and Pensions Committee (HELP). Grace has worked on the HELP Committee since 2011, previously working for Ranking Member Enzi, focusing on FDA policy.

She's worked on major legislative efforts including the FDA Safety and Innovation Act, 21st Century Cures Act, and Opioid Crisis Response Act.

She received her BS in Biomedical Engineering and Master of Public Policy (MPP) from the University of Virginia.



JAMES GULLEY, MD, PhD

Chief, *Genitourinary Malignancies Branch*, Director, *Medical Oncology Services, Center for Cancer Research* National Cancer Institute
National Institutes of Health

Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.

Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 200 trials including dozens of first-in-human studies. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a number of vaccines and antibodies including avelumab (Bavencio) and bintrafusp alfa. His clinical studies led to the approval of avelumab in 2017.

Dr. Gulley has authored more than 300 scientific papers and book chapters, edited 4 books and has made hundreds of presentations at national and international meetings.



WILLIAM L. HENRICH, MD, MACP

President and Professor of Medicine,
UT Health San Antonio

William L. Henrich, MD, MACP, a specialist in kidney diseases, has served as the president of the University of Texas Health Science Center at San Antonio (now called UT Health San Antonio) since 2009. Dr. Henrich is the inaugural holder of the John P. Howe, III, MD, Distinguished Chair in Health Policy.

He received his undergraduate degree from Columbia University and his medical degree from Baylor College of Medicine, and later completed a residency in Internal Medicine at the University of Oregon Medical School and a fellowship in Nephrology at the University of Colorado School of Medicine.

Dr. Henrich served as Professor of Medicine at The University of Texas Southwestern School of Medicine, as Professor and Chair of Medicine at the Medical College of Ohio, and as the Theodore Woodward Professor and Chairman of the Department of Medicine at The University of Maryland School of Medicine in Baltimore. He became the Dean of the School of Medicine and Vice President for Medical Affairs at UT Health San Antonio in 2006. He is the author of over 300 articles and chapters, and the founding editor of the popular dialysis textbook "Henrich's Principles and Practice of Dialysis". He has research interests in hemodynamic stability during dialysis and the intrarenal renin-angiotensin system.

Panelists



CLIFFORD HUDIS, MD

Chief Executive Officer
American Society of Clinical Oncology (ASCO)

Dr. Hudis is the CEO of the American Society of Clinical Oncology, the largest professional society in the world dedicated to education, research, and quality of care for patients with cancer. Among many other current initiatives, ASCO is developing CancerLinQ, a not-for-profit subsidiary that will organize real world big data into usable knowledge, personalized for individual patients.

Before his move to ASCO, Dr. Hudis served for nearly two decades as the Chief of the Breast Medicine Service and Attending Physician at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City where he was also a Professor of Medicine at the Weill Medical College of Cornell University. He was co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, and a former Associate Editor of the *Journal of Clinical Oncology*. He also served as MSKCC's Vice President for Government Relations and Chief Advocacy Officer and he continues to maintain a limited clinical practice at that institution.



STEPHEN ALBERT JOHNSTON

CEO, *Calviri, Inc.*;
Director, *Center for Innovations in Medicine, Biodesign Institute, Arizona State University*

Stephen Albert Johnston is CEO of Calviri, Inc a spin out of the Biodesign Institute at ASU. Calviri's goal is to end deaths from cancer worldwide. The most feasible way to do this is through early detection and treatment of cancer. Toward this end, Calviri has developed a simple chip-based blood assay for early diagnosis of any cancer. This diagnostic is a companion to an off the shelf vaccine for the cancer diagnosed. More ambitiously, they have also developed vaccines for preventing cancer in the first place. Currently, one such vaccine is being tested in a large-scale dog clinical trial. Importantly, all these products could be priced so that anyone in the world could have access to them.



ARTHUR A. KLEIN, MD

President
Mount Sinai Health Network

Arthur A. Klein, MD is President of the Mount Sinai Health Network. In this role, he oversees the institution's network of more than 150 clinical relationships, including 18 affiliated hospitals, five nursing homes, and 12 physician group practices throughout New York City, Nassau, Suffolk, and Westchester counties. Dr. Klein also oversees national and international initiatives for Mount Sinai and serves as Executive Vice President of The Mount Sinai Hospital, and Executive Vice President of the Icahn School of Medicine at Mount Sinai.

Previously, Dr. Klein served as the Regional Executive Director, Western Region of the North Shore-LIJ Health System; Senior Vice President for Pediatric Services of the North Shore-LIJ Health System; Chief of Staff and Executive Director of the Steven and Alexandra Cohen Children's Medical Center of New York; and the Philip Lanzkowsky Professor of Pediatrics, Hofstra North Shore-LIJ Medical School. Prior to those appointments, he was an Associate Dean for Strategy and Special Projects at the Warren Alpert Medical School of Brown University where he also was a Senior Vice President and Chief Physician Officer at Lifespan.

Dr. Klein served as Executive Vice President and Chief Operating Officer at the New York-Presbyterian Healthcare System and as Executive Vice Chairman of the Department of Pediatrics at New York Hospital-Cornell Medical Center, where he completed his residency and fellowship. He received his undergraduate degree from the Massachusetts Institute of Technology, and his MD from SUNY Downstate Medical Center.



MIKE MEYER

Founder and President
Meyer Consulting

Mike Meyer has spent his career serving healthcare organizations in their strategic and human capital initiatives. Over the years he has built multiple firms. Meyer is known for his work with Board- and C-Suite-level executives, his extensive network of senior healthcare executives, and his in-depth knowledge about healthcare, how it is funded and delivered, and the policy changes that drive the industry. His work has positively changed organizations, driven top- and bottom-line growth, and created new healthcare businesses.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing strategic/partnership consulting, executive search and educational programming. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Banner Health, Blue Cross Blue Shield Association, Horizon BCBS, MD Anderson Cancer Center, Summit Medical Group, NY Genome Center and numerous other academic centers, large providers and payors, physician groups, and other for- and not-for-profit companies. In 2019 the executive search practice of Meyer Consulting was acquired by Westwood & Wilshire.

Meyer is the founder of the Cancer Care at the Crossroads Summit held each year in NYC. Before forming Meyer Consulting, Meyer was a senior partner and board member of Witt/Kieffer. Prior he was vice president in charge of the New York office of Amherst Associates, and director with Medicus Systems, a consulting division of Wittaker Corporation.

Meyer has served on for-profit and not-for-profit Boards. He was a board member of Summit Select, part of Summit Medical Group which was recently sold to Warburg Pincus. He was the board chair and co-founder of the Institute for Mental Health Research (www.imhr.org). He has been widely quoted on healthcare, mental health and retiree topics in healthcare and general publications.



MICHAEL F. MURRAY, MD

Director of Clinical Operations
Center for Genomic Health, Yale School of Medicine

Dr. Mike Murray's work is focused on understanding the value of using DNA-based screening of populations in order to identify those individuals with a cancer and heart disease risk for which preventive-care interventions are available. He joined Yale in 2018 as the director of clinical operations in the newly formed Yale Center of Genomic Health.

In 2019 he led the launch of Generations, a Yale population health project that will enroll at least 100,000 volunteers. This project links genomic data with electronic health data in order to enable both research and patient care delivery.

From 2013 to 2018 he was the Geisinger Health System's first director of clinical genomics. At Geisinger he led the design and implementation of the GenomeFIRST program. GenomeFIRST delivers risk results regarding cancer and heart disease to patients and their healthcare providers, and then guides their clinical management in ongoing screening and prevention.

Prior to his time at Geisinger he was the Clinical Chief of Genetics at Brigham and Women's Hospital for nine years while on the faculty at Harvard Medical School. He is a physician and is board certified in Internal Medicine and Medical Genetics.



BENJAMIN G. NEEL, MD, PhD

Professor of Medicine; Director
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

Benjamin Neel is the Director of the Laura and Isaac Perlmutter Cancer Center and Professor of Medicine at NYU Langone Health in New York City. His research focuses on cellular signaling, with a particular interest in the biology and regulation of protein-tyrosine kinases and protein-tyrosine phosphatases, the role of RAS/ERK pathway mutations in developmental disease and malignancy, and the biology of ovarian cancer.

Dr. Neel earned his PhD in viral oncology from The Rockefeller University in 1982 and his MD from Cornell University Medical School the following year. His graduate work on oncogene activation by slowly transforming RNA tumor viruses had major impact on the field. He previously held positions as William B. Castle Chair of Medicine at Harvard Medical School and Director of Hematology-Oncology Research and Head of the Cancer Biology Program at Beth Israel Deaconess Medical Center, Boston and as Director of Research at Princess Margaret Cancer Center and Professor of the Medical Biophysics at the University of Toronto, Ontario, Canada.

He has authored >240 primary papers and 33 reviews, many in leading journals including Cell, Molecular Cell, Developmental Cell, Science, Nature, Nature Medicine and Nature Genetics. His work has been cited >46,000 times (h-index, 110). He is an elected member of the American Association of Physicians, former Program Chair of the Annual Meeting and Member of Board of Directors of AACR, recipient of the Gertrude Elion Award of AACR and the Premier of Ontario Summit Award, and co-founder of Northern Biologics, a company focusing on antibody therapeutics for cancer and Navire Pharmaceuticals, which is developing SHP2 inhibitors for cancer.

Panelists



EILEEN O'DONNELL, MBA

Executive Director
Northwell Health Cancer Institute

Eileen O'Donnell is the Executive Director of the Northwell Health Cancer Institute with administrative, operational and strategic oversight of cancer care delivery at Northwell Health. She has over 25 years of experience in healthcare, spending a majority of that time working on large transformational engagements. She has traveled internationally to assist health care systems with their operational and clinical care delivery. She started her career as an oncology nurse and worked with children with brain and spinal cord tumors before transitioning to administration early in her career.

Ms. O'Donnell worked at PricewaterhouseCoopers where she was a Director in the Health Advisory Practice, working closely with healthcare organizations to navigate a complex and rapidly changing environment. Prior to PwC, Ms. O'Donnell was Vice President at Nexera Consulting, a wholly-owned subsidiary of the Greater New York Hospital Association. She also held various nursing and administrative leadership positions within large academic medical centers, as well as mid-sized community hospitals. Her areas of expertise include mergers and acquisitions, productivity and strategic planning, transformational management, care management, contract negotiations, process improvement, clinical support, and supply chain operations.

Ms. O'Donnell earned a Master of Business Administration from Cornell University, a Master of Arts from Columbia University and a Bachelor of Science in Nursing from Fairfield University.



KETAN PARANJAPE, MBA

Vice President of Diagnostic Information Solutions
Roche Diagnostics

Ketan is the VP of Diagnostics Information Solutions (DIS) Commercial Operations at Roche. The DIS business aims to harness the power of data, diagnostics and other critical information to support better clinical decisions.

Ketan holds MS degrees in Electrical Engineering and Computer Sciences from the University of Wisconsin and an MBA from the University of Oregon, where he was the class valedictorian. He also completed the Stanford Executive Program as well as coursework in Healthcare Management at the Harvard School of Public Health.

He is an Honorary Research Fellow at the Imperial College London and Technical Advisor in Artificial Intelligence at Lee Kong Chian School of Medicine Singapore. Ketan is a certified Paramedic and resides in Indianapolis, Indiana with his wife and son.



HAROLD L. PAZ, MD, MS

EVP and Chancellor for Health Affairs
The Ohio State University

Harold L. Paz, MD, MS is the first to serve in the position of Executive Vice President (EVP) and Chancellor for Health Affairs at The Ohio State University, and Chief Executive Officer (CEO) of the Ohio State Wexner Medical Center. At Ohio State, Dr. Paz leads all seven health science colleges and serves as CEO of the \$4 billion Wexner Medical Center enterprise, which includes seven hospitals, a nationally ranked college of medicine, more than 20 research institutes, multiple ambulatory sites, an accountable care organization, and a health plan.

Before joining Ohio State in June 2019, Dr. Paz was EVP and CMO at Aetna, where he led clinical strategy and policy at the intersection of all of Aetna's domestic and global businesses. Prior to joining Aetna in 2014, Dr. Paz served as President and CEO of the Penn State Hershey Health System, SVP for Health Affairs at Pennsylvania State University, and Dean of its College of Medicine for eight years. Before his appointment at Penn State, he spent 11 years as dean of the Robert Wood Johnson Medical School and CEO of the Robert Wood Johnson University Medical Group.

Dr. Paz is currently on the board of Research!America and is past chair of the Board of Directors of the Association of Academic Health Centers, a former board member of the Association of American Medical Colleges (AAMC), and chair of the AAMC Council of Deans. Dr. Paz received his medical degree from the University of Rochester School of Medicine and Dentistry and completed his residency at Northwestern University, where he served as Chief Medical Resident. He was a Eudowood Fellow in pulmonary and critical care medicine at Johns Hopkins Medical School and a postdoctoral fellow in environmental health science at Johns Hopkins School of Hygiene and Public Health.



STEVEN PESKIN, MD, MBA, FACP

Executive Medical Director
Horizon Blue Cross Blue Shield of New Jersey

Steven R. Peskin, MD is the Executive Medical Director, Population Health at Horizon Blue Cross Blue Shield of New Jersey. His expertise encompasses physician leadership, population health management, clinical and operational performance improvement in health care, medical education and scientific communications. He has been one of the driving forces for the creation of and successful maturation of value-based models in New Jersey.

Dr. Peskin is an Associate Clinical Professor in the Department of Medicine at Rutgers Robert Wood Johnson Medical School. He is a clinical preceptor at The Eric B. Chandler Clinic for interns and residents in Internal Medicine. Dr. Peskin assists with the Population Health and business of medicine training for the Rutgers RWJ Internal Medicine physicians in training.

Dr. Peskin received his bachelor's degree from The University of North Carolina Chapel Hill and medical degree from Emory University School of Medicine. He completed residency at Saint Elizabeth's Medical Center in Boston and holds an MBA from the Sloan School of Management at Massachusetts Institute of Technology.



PETER PISTERS, MD

President
The University of Texas MD Anderson Cancer Center

Peter Pisters, MD took the helm as president of The University of Texas MD Anderson Cancer Center in 2017, and forged a new path forward in the fight to end cancer by transforming the culture of the nation's top cancer center. With a boundless appetite for listening and learning, Dr. Pisters has built an inclusive environment within the organization while also prioritizing relationships with government, industry and community partners to thrive in the rapidly changing health care landscape.

A renowned cancer surgeon, researcher, professor and administrator, Dr. Pisters established his career at MD Anderson, serving over 20 years as a faculty member and medical director for the center's expansion in metropolitan Houston. He left MD Anderson to serve as president and CEO of the University Health Network in Toronto, Canada's largest research hospital, before returning to MD Anderson in 2017. He says the privilege of caring for cancer patients was the most impactful preparation he has had for his current role.

With MD Anderson's 22,000 people as his priority, Dr. Pisters has cultivated a diverse executive team and championed benefits and continuous growth for employees. Dr. Pisters was named a Top CEO by Glassdoor in 2018 and 2019-the only health care leader in Texas to make the top 100 list.

Dr. Pisters earned his medical degree at the Schulich School of Medicine and Dentistry in Canada and did postgraduate work at Memorial Sloan Kettering Cancer Center in New York. He received a master's degree in health care management at the Harvard T.H. Chan School of Public Health in Boston.



JONATHAN D. ROCKOFF

Deputy Chief of the Health and Science Bureau
The Wall Street Journal

Jonathan D. Rockoff is the deputy chief of the Health and Science Bureau at The Wall Street Journal. Based in New York City, he helps edit a group of reporters that cover science, medicine and healthcare. Previously for the newspaper, Jonathan reported on the pharmaceutical and biotechnology industries. He was a member of a team of reporters that was a finalist for the Pulitzer Prize for their coverage of drug pricing. Jonathan has also worked at The Baltimore Sun and The Providence Journal. He is a graduate of Princeton University and the University of Virginia School of Law.

Panelists



MACE L. ROTHENBERG, MD

Chief Medical Officer, Pfizer
Pfizer Inc

As Chief Medical Officer of Pfizer, Mace Rothenberg leads Pfizer's Worldwide Medical & Safety organization that is responsible for ensuring that patients, physicians, and regulatory agencies are provided with information on the safe and appropriate use of Pfizer medications. Outside of his responsibilities at Pfizer, Dr. Rothenberg co-chairs the Life Sciences Consortium of the CEO Roundtable on Cancer and is a member of the NYU School of Medicine's Alumni Board of Governors.

Prior to becoming Pfizer's CMO, Dr. Rothenberg was Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016 and Chief Development Officer for Oncology from 2016 to 2018. During that period, Dr. Rothenberg's organization was responsible for the successful development and regulatory approval of 11 new cancer medicines.

Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society honoring him as one of the nation's top cancer caregivers, and the Statesman Award from the American Society of Clinical Oncology honoring him for more than 20 years of service to the organization, the specialty of oncology and cancer patients. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982. He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute. Dr. Rothenberg served on the faculties of the University of Texas Health Science Center—San Antonio (1991-1998) and Vanderbilt University (1998-2008).



MARGARET B. ROW, MD, MBA, FACP

Clinical Chief of Oncology
Summit Medical Group Cancer Center

Dr. Margaret B. Row, clinical chief of oncology for Summit Medical Group Cancer Center, is a proven physician leader with expertise in visioning, developing and operating clinical programs. Row has extensive experience in clinical operations across the entire healthcare spectrum, network development, physician recruitment, leadership development, clinical quality and value.

Dr. Row was Vice President Clinical Operations for the MD Anderson Cancer Network (2012 to 2018) and was responsible for the successful development, implementation and operations of MD Anderson Cancer Network clinical programs throughout the US and the world. These customized integrated multidisciplinary oncology programs, executed in five countries and with eight domestic healthcare partners, were connected by her team to the MDACC main campus. During her tenure, the Network contributed significantly to the MDACC institutional margin.

After graduating with distinction from George Washington University of Medicine in 1994, Dr. Row completed her residency training in Internal Medicine at Baylor College of Medicine. She completed a MBA in 2007 at the McCombs School of Business at the University of Texas. She is a fellow of the American College of Physicians, board certified in Internal Medicine, and-2008).



MICHEL SADELAIN, MD, PhD

Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center

Dr. Sadelain has made major contributions to the generation and optimization of CAR T cells to treat cancer, as well as the development of stem cell therapies for blood disorders. Dr. Sadelain's work has focused on developing novel strategies to extend survival of CAR cells in the body and enable T cells with increased potency to overcome the resistance imposed by tumor and other cells in the tumor microenvironment.

Dr. Sadelain is founding director of the Center for Cell Engineering and head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center (MSKCC), where he holds the Stephen and Barbara Friedman Chair. Dr. Sadelain is also a member of the departments of medicine and pediatrics at Memorial Hospital and the molecular pharmacology and chemistry program of the Sloan Kettering Institute.

Dr. Sadelain received his MD from the University of Paris, France, in 1984 and his PhD from the University of Alberta, Canada, in 1989. After completing a clinical residency at the Centre Hospitalier Universitaire Saint-Antoine in Paris, Dr. Sadelain carried out a postdoctoral fellowship with Richard Mulligan, PhD, at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, before joining MSKCC in 1994 as an assistant member. He has authored more than 150 scientific papers and book chapters.



ANDREW SCHMELTZ, MBA

Global President and General Manager, *Pfizer Oncology*
Pfizer Inc

Andrew ("Andy") Schmeltz is the Global President and General Manager of Pfizer Oncology, responsible for an industry-leading, innovative portfolio of cancer medicines. He is a forward-looking leader who empowers and motivates people to strive for excellence every day. Mr. Schmeltz's vision for Pfizer Oncology is to change the trajectory of cancer.

Under Mr. Schmeltz's leadership, Pfizer Oncology has experienced tremendous and continued growth. In early 2019, Andy championed the \$11.4 billion acquisition of Array BioPharma Inc., to strengthen the division's leadership in cancer care and expand the company's portfolio into additional areas of unmet medical need. Following the acquisition, the Pfizer Oncology portfolio now consists of 22 medicines and biosimilars across more than 30 indications, including breast, prostate, blood, kidney and lung cancers, and melanoma.

Mr. Schmeltz's career reflects his belief in being authentic, building consensus and modeling the behaviors he wants to see in others. As a 16-year Pfizer veteran, he has held multiple leadership positions throughout the organization. Prior to assuming his current role, Mr. Schmeltz was the head of Pfizer's Patient & Health Impact division, accountable for ensuring patients around the world gain affordable, timely access to medicines. He also held the role of Chief Commercial Officer for Pfizer Internal Medicine, with accountability for the franchise's \$9 billion global portfolio of medicines, spanning cardiovascular metabolic, neuroscience and pain.

Prior to Pfizer, Mr. Schmeltz spent seven years at Abbott Laboratories in several senior positions. He holds a BA in economics from Columbia University, and his MBA from the University of Chicago's Booth School of Business.



JACQUE SOKOLOV, MD

Chairman and CEO,
SSB Solutions

Jacque J. Sokolov, MD is chairman and chief executive officer of SSB Solutions, Inc., a US based, diversified healthcare management, development and financial services company currently operating in over 20 states.

Following his formal training as an academic cardiologist, Dr. Sokolov started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation (NYSE:EIX). He currently serves or has served in multiple board capacities for Public Companies including Hospira (NYSE: HSP), MedCath (NASDAQ: MDTH), and PhyAmerica (NYSE: ERDR); Private Companies including GlobalMed, Zoonie (SMG), MyHealthDirect, NeuLife Neurological Services (NeuLife), Calviri, AKOS, the Trill Project and SSB wholly owned companies; and Non Profit Organizations including Phoenix Children's Hospital, The Health Futures Council at ASU, The Executive Committee of the Board of Councilors for the USC School of Pharmacy, The National Health Foundation, the American College of Medical Quality, the National Fund for Medical Education, and the National Business Group on Health and the White House Health Project.

Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School. He previously held and currently holds academic appointments and advisory board responsibilities in the Schools of Medicine, Business and Public Health at Harvard, the Massachusetts Institute of Technology, the University of Pennsylvania, the University of California, Los Angeles, and the University of Southern California.



GLEN STETTIN, MD

Senior Vice President and Chief Innovation Officer, *Express Scripts* and *Cigna Health Services*

Glen Stettin, MD leads Express Scripts' development of solutions that help employers and other health-plan sponsors to reduce costs while improving members' health outcomes. His responsibilities include research, analytics, reporting, formulary and trend management, as well as clinical product development including Consumerology® and specialized care through Express Scripts' Therapeutic Resource Centers®.

A board-certified physician and business leader, Dr. Stettin has a passion for innovation and evidence-based, data-driven healthcare. He previously served as Chief Medical Officer at Medco, and has practiced internal medicine and emergency medicine in New Jersey and California. He completed his residency in internal medicine and fellowship training at the University of California, San Francisco, where he also served as Medical Chief Resident at Moffitt Hospital, and as a Robert Wood Johnson Clinical Scholar.

Panelists



MAUREEN E. SULLIVAN, MPP

Chief Strategy and Innovation Officer,
Blue Cross Blue Shield Association

Maureen Sullivan has overall accountability for the Blue Cross Blue Shield Association's (BCBSA's) strategy and research, brand, B2B marketing, communications, innovation and educational programs. In this capacity, she leads several teams in providing wide-ranging services and strategic counsel to BCBSA leadership and Blue Cross and Blue Shield (BCBS) member companies.

Among the thought leadership initiatives Sullivan drives on behalf of the BCBS System are efforts to effectively leverage BCBS data to bring new insights to healthcare. This suite of programs includes the BCBS Health Index, a first-of-its-kind measure of community and national health; the Health of America report series, which highlights data-driven information on critical health topics; and the Alliance for Health Research, an innovative collaboration with leading academic institutions.

Sullivan also supports BCBS companies in their efforts to transition healthcare to become more patient-focused and leverage new capabilities through innovative partnerships with consumer technology leaders. Her strategic guidance spans development of new solutions within BCBSA and across the BCBS System, as well as multiple initiatives to further strengthen the BCBS brand across all lines of business, from individual consumers to large national employers.

Sullivan earned a master's degree in public policy from the John F. Kennedy School of Government at Harvard University where she was a Kennedy Fellow. She also holds a bachelor's degree with honors from Albertus Magnus College in New Haven, Connecticut.



RICHARD SULLIVAN, MD, PhD

Director, *Institute for Cancer Policy*;
Professor of Cancer & Global Health, *King's College London*

Professor Richard Sullivan studies health systems, particularly NCD policy and the impact of conflict on health. He is Professor of Cancer and Global Health at King's College London, and Director of the Institute of Cancer Policy (ICP) and co-Director of the Conflict and Health Research Group. As well as holding a number of Visiting Chairs, Richard is an NCD advisor to the WHO, civil-military advisor to Save the Children, and a member of the National Cancer Grid of India.

His research focuses on global cancer policy and planning, and health systems strengthening, particularly conflict ecosystems. He is principle investigator on research programs ranging from automated radiotherapy planning for low resource settings to use of augmented/virtual reality for cancer surgery, through to political economy to build affordable, equitable cancer control plans. Richard has led five Lancet Oncology Commissions and worked on four others. He is currently co-leading Lancet Oncology commissions on the Future of Cancer Research in Europe and Cancer Care in Conflict. In conflict systems, his research teams have major programs in capacity building in conflict medicine across the Middle East and North Africa (r4hc-mena.org), as well as studies of the basic package of health services in Afghanistan, civil-military co-operation in health security, polio eradication and insecurity in Pakistan, and use of intelligence in high security disease outbreaks.

Professor Sullivan qualified in medicine and trained in surgery (urology), gaining his PhD from University College London. He was also clinical director of Cancer Research UK between 1999 and 2008. Following a period at the London School of Economics working on complex healthcare systems he moved to King's College London in 2011.



CCX 2020



MEYER CONSULTING

Phone (406) 531.5505

Fax (480) 614.5660

Website www.meyerconsultinginc.com

CORPORATE OFFICE

Meyer Consulting, LLC

5665 N. Scottsdale Road, Suite 110

Scottsdale, AZ 85250



Meyer Consulting is an international health care consulting and recruiting firm that brings leading experts together in collaborative settings to build better health care solutions.